Search
for
Did you mean Phosphodiesterase Inhibitors?
Sort by
Research 30 of 563
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- FDA approves label addition for PDE-5 inhibitor
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
- Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Lower Urinary Tract Symptoms: What’s New in Medical Treatment?
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Adverse effects of common medications on male fertility
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations
- Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
- Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
- Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach
- Physcion, a novel inhibitor of 5α-reductase that promotes hair growth in vitro and in vivo
- Cyclin-dependent kinase inhibitors, p21waf1/cip1 and p27kip1, are expressed site- and hair cycle-dependently in rat hair follicles
- Caffeine’s Mechanisms of Action and Its Cosmetic Use
- When two plus two must not equal four
- Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- The Effect of 5 -Reductase Inhibitors on Erectile Function
- Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
- Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis